This website is intended for an international audience. To view your own country’s website if available, please select your country from the list provided.
Close
Close
Close
Close
Close
Close

Theramex News

Close

Our diverse portfolio helps us deliver on our commitment to Women's Health

Close

Get in touch

Close

Careers

Theramex news

Stay up to date with the latest news from Theramex.

11 December 2023

Theramex Announces Completion of its Acquisition of the Femoston® and Duphaston® Products in Europe (ex-UK) from Viatris. 

Read more

1 December 2023

Theramex Office Opening and Panel Discussion

Read more

2 October 2023

Theramex Announces Agreement to Acquire the European Rights to Duphaston® and Femoston® From Viatris, Inc.

Read more

14 August 2023

Theramex’s statement on the Women’s Health Strategy’s (WHS) one year anniversary

Read more

8 March 2023

Theramex enters into an exclusive licensing agreement with Radius Health Inc, to commercialise ELADYNOS® in the European Economic Area, the United Kingdom, Australia and Brazil

Read more

17 June 2022

Theramex Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the treatment of symptoms of Uterine Fibroids

Read more